--- title: "Fat Loss Peptides | PepTracker Pro" url: https://peptrackerpro.com/benefits/fat-loss description: "Peptides discussed for body fat reduction and metabolic rate." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) # Fat Loss Peptides Peptides discussed for body fat reduction and metabolic rate. ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/5-amino-1mq \+ Compare: https://peptrackerpro.com/compare?select=5-amino-1mq Track in App: https://app.peptrackerpro.com/?add=5-amino-1mq ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-100 \+ Compare: https://peptrackerpro.com/compare?select=alv-100 Track in App: https://app.peptrackerpro.com/?add=alv-100 ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### AOD-9604 Medium Evidence A modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Joint Health: https://peptrackerpro.com/benefits/joint-health View Details: https://peptrackerpro.com/peptides/aod-9604 \+ Compare: https://peptrackerpro.com/compare?select=aod-9604 Track in App: https://app.peptrackerpro.com/?add=aod-9604 ### ASC30 Low Evidence An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron. View Details: https://peptrackerpro.com/peptides/asc30 \+ Compare: https://peptrackerpro.com/compare?select=asc30 Track in App: https://app.peptrackerpro.com/?add=asc30 ### ASC35 Low Evidence A next-generation once-monthly GLP-1R/GIPR dual agonist peptide with a 14-day half-life (6-fold longer than tirzepatide) and 71% greater weight loss than tirzepatide in preclinical models. View Details: https://peptrackerpro.com/peptides/asc35 \+ Compare: https://peptrackerpro.com/compare?select=asc35 Track in App: https://app.peptrackerpro.com/?add=asc35 ### ASC36 Low Evidence A next-generation once-monthly amylin receptor agonist peptide with a 32-day half-life and 91% greater weight loss than petrelintide in preclinical models. IND filing expected Q2 2026. View Details: https://peptrackerpro.com/peptides/asc36 \+ Compare: https://peptrackerpro.com/compare?select=asc36 Track in App: https://app.peptrackerpro.com/?add=asc36 ### ASC37 Low Evidence A next-generation once-monthly GLP-1R/GIPR/GCGR triple peptide agonist with 5-fold greater potency than retatrutide and a 17-day half-life enabling monthly dosing. IND filing expected Q2 2026. View Details: https://peptrackerpro.com/peptides/asc37 \+ Compare: https://peptrackerpro.com/compare?select=asc37 Track in App: https://app.peptrackerpro.com/?add=asc37 ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### ASC47 Low Evidence A first-in-class adipose-targeted thyroid hormone receptor beta (THRβ) agonist designed for muscle-preserving weight loss. Phase 1 data at ECO 2026 showed 111.8% greater weight loss when combined with semaglutide vs semaglutide alone. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/asc47 \+ Compare: https://peptrackerpro.com/compare?select=asc47 Track in App: https://app.peptrackerpro.com/?add=asc47 ### AT7687 Low Evidence A first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/at7687 \+ Compare: https://peptrackerpro.com/compare?select=at7687 Track in App: https://app.peptrackerpro.com/?add=at7687 ### Berobenatide Medium Evidence A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide. View Details: https://peptrackerpro.com/peptides/berobenatide \+ Compare: https://peptrackerpro.com/compare?select=berobenatide Track in App: https://app.peptrackerpro.com/?add=berobenatide ### BI 3034701 Low Evidence A potential first-in-class triple GLP-1, GIP, and NPY2 receptor agonist peptide entering Phase 2 development mid-2026 for obesity, developed by Boehringer Ingelheim using Gubra-discovered technology. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/bi-3034701 \+ Compare: https://peptrackerpro.com/compare?select=bi-3034701 Track in App: https://app.peptrackerpro.com/?add=bi-3034701 ### Bimagrumab Medium Evidence An anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Weight Management (https://peptrackerpro.com/benefits/weight-management)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/bimagrumab \+ Compare: https://peptrackerpro.com/compare?select=bimagrumab Track in App: https://app.peptrackerpro.com/?add=bimagrumab ### BRP Low Evidence A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models. Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/brp \+ Compare: https://peptrackerpro.com/compare?select=brp Track in App: https://app.peptrackerpro.com/?add=brp ### BWB3054 Low Evidence A GIP/glucagon dual agonist that achieves weight loss comparable to retatrutide without GLP-1 receptor activity, potentially eliminating GI side effects. Published in Molecular Metabolism (April 2026). View Details: https://peptrackerpro.com/peptides/bwb3054 \+ Compare: https://peptrackerpro.com/compare?select=bwb3054 Track in App: https://app.peptrackerpro.com/?add=bwb3054 ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### CJC-1295 Medium Evidence A growth hormone releasing hormone analog studied for stimulating growth hormone secretion. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Recovery (https://peptrackerpro.com/benefits/recovery)Sleep (https://peptrackerpro.com/benefits/sleep)+1 more View Details: https://peptrackerpro.com/peptides/cjc-1295 \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295 Track in App: https://app.peptrackerpro.com/?add=cjc-1295 ### CJC-1295 (DAC) Medium Evidence A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification. View Details: https://peptrackerpro.com/peptides/cjc-1295-dac \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295-dac Track in App: https://app.peptrackerpro.com/?add=cjc-1295-dac ### Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. View Details: https://peptrackerpro.com/peptides/conveglipron \+ Compare: https://peptrackerpro.com/compare?select=conveglipron Track in App: https://app.peptrackerpro.com/?add=conveglipron ### Cotadutide Medium Evidence A once-daily GLP-1/glucagon dual receptor agonist studied for MASH, obesity, and type 2 diabetes with demonstrated liver fat reduction and antifibrotic activity. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/cotadutide \+ Compare: https://peptrackerpro.com/compare?select=cotadutide Track in App: https://app.peptrackerpro.com/?add=cotadutide ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. View Details: https://peptrackerpro.com/peptides/cx11 \+ Compare: https://peptrackerpro.com/compare?select=cx11 Track in App: https://app.peptrackerpro.com/?add=cx11 ### DA-1726 Low Evidence A novel once-weekly GLP-1/glucagon dual receptor agonist showing rapid weight loss in Phase 1 trials with preserved lean body mass and direct liver benefits. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/da-1726 \+ Compare: https://peptrackerpro.com/compare?select=da-1726 Track in App: https://app.peptrackerpro.com/?add=da-1726 ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ecnoglutide \+ Compare: https://peptrackerpro.com/compare?select=ecnoglutide Track in App: https://app.peptrackerpro.com/?add=ecnoglutide ### Elecoglipron Medium Evidence An investigational, once-daily oral small-molecule GLP-1 receptor agonist from AstraZeneca that delivered up to about 11.8% weight loss at 36 weeks in people with obesity or overweight and strong blood-sugar control in type 2 diabetes, and is now advancing into a large Phase 3 program. Unlike semaglutide and tirzepatide - which are injectable peptides - elecoglipron is a small chemical molecule that mimics the natural GLP-1 hormone at its receptor in the gut and hypothalamus, so it can be taken as a pill with no food or fasting restrictions and is easier and cheaper to manufacture at global scale than peptide drugs. In the Phase 2b VISTA trial (n=310) the 75 mg once-daily regimen produced an average body-weight reduction of 10.5% at 26 weeks (vs 0.6% placebo) that had not plateaued, reaching about 11.8% at 36 weeks, with up to 88.8% of participants achieving at least 5% weight loss. In the Phase 2b SOLSTICE trial in type 2 diabetes (n=404) the 75 mg regimen cut HbA1c by 1.9% at 26 weeks (vs 0.2% placebo) - with roughly 90% of participants reaching an HbA1c below 7% - alongside 7.7% weight loss, numerically ahead of an open-label oral semaglutide 14 mg comparator arm. Side effects were the familiar GLP-1 class gastrointestinal symptoms (nausea, constipation, diarrhea, vomiting), mostly mild to moderate, with infrequent discontinuations and no liver safety signals. Both trials were presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans and published simultaneously in The Lancet, and on June 8, 2026 AstraZeneca announced elecoglipron would move into an extensive Phase 3 program - the EMBOLD obesity trials and the ELUMINATE type 2 diabetes trials (including combination with dapagliflozin), plus cardiovascular and kidney outcome studies. Elecoglipron is an investigational prescription-stage medicine - it is not approved anywhere and is not a supplement or research chemical. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Glycemic Control (https://peptrackerpro.com/benefits/glycemic-control)+1 more View Details: https://peptrackerpro.com/peptides/elecoglipron \+ Compare: https://peptrackerpro.com/compare?select=elecoglipron Track in App: https://app.peptrackerpro.com/?add=elecoglipron ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. View Details: https://peptrackerpro.com/peptides/eloralintide \+ Compare: https://peptrackerpro.com/compare?select=eloralintide Track in App: https://app.peptrackerpro.com/?add=eloralintide ### Enicepatide Medium Evidence An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity. Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)+1 more View Details: https://peptrackerpro.com/peptides/enicepatide \+ Compare: https://peptrackerpro.com/compare?select=enicepatide Track in App: https://app.peptrackerpro.com/?add=enicepatide ### Garetosmab Medium Evidence Garetosmab (REGN2477) is Regeneron's investigational fully human anti-activin A monoclonal antibody. In the Phase 3 OPTIMA trial in adults with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), it cut new heterotopic bone lesions by ~90-94% and reduced new-lesion volume by >99% versus placebo; its BLA was accepted for FDA Priority Review with an August 2026 target action date. The same activin A blockade also makes garetosmab the muscle-preserving partner to trevogrumab and semaglutide in the Phase 2 COURAGE obesity program. Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/garetosmab \+ Compare: https://peptrackerpro.com/compare?select=garetosmab Track in App: https://app.peptrackerpro.com/?add=garetosmab ### GDF-15 Receptor Agonists Medium Evidence A new class of peptide-based weight loss therapeutics that act through the GFRAL/RET receptor in the brainstem, representing a non-GLP-1 mechanism for appetite suppression and energy expenditure regulation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/gdf15-agonists \+ Compare: https://peptrackerpro.com/compare?select=gdf15-agonists Track in App: https://app.peptrackerpro.com/?add=gdf15-agonists ### GEP-44 Low Evidence A novel triple agonist peptide targeting GLP-1 and peptide YY receptors Y1 and Y2, designed to suppress appetite and improve glycemic control while avoiding GI side effects common to first-generation GLP-1 drugs. View Details: https://peptrackerpro.com/peptides/gep-44 \+ Compare: https://peptrackerpro.com/compare?select=gep-44 Track in App: https://app.peptrackerpro.com/?add=gep-44 ### GHRP-6 Medium Evidence A growth hormone secretagogue that also stimulates appetite through ghrelin receptor activation. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Fat Loss: https://peptrackerpro.com/benefits/fat-loss Recovery: https://peptrackerpro.com/benefits/recovery Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/ghrp-6 \+ Compare: https://peptrackerpro.com/compare?select=ghrp-6 Track in App: https://app.peptrackerpro.com/?add=ghrp-6 ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. View Details: https://peptrackerpro.com/peptides/glp1-gip-lani \+ Compare: https://peptrackerpro.com/compare?select=glp1-gip-lani Track in App: https://app.peptrackerpro.com/?add=glp1-gip-lani ### IGF-1 LR3 Medium Evidence A modified form of IGF-1 with extended half-life, studied for muscle growth and tissue development. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Recovery: https://peptrackerpro.com/benefits/recovery Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/igf-1-lr3 \+ Compare: https://peptrackerpro.com/compare?select=igf-1-lr3 Track in App: https://app.peptrackerpro.com/?add=igf-1-lr3 ### Ipamorelin Medium Evidence A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides. View Details: https://peptrackerpro.com/peptides/ipamorelin \+ Compare: https://peptrackerpro.com/compare?select=ipamorelin Track in App: https://app.peptrackerpro.com/?add=ipamorelin ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. View Details: https://peptrackerpro.com/peptides/kai-7535 \+ Compare: https://peptrackerpro.com/compare?select=kai-7535 Track in App: https://app.peptrackerpro.com/?add=kai-7535 ### LIPO-C Low Evidence A lipotropic injection blend containing methionine, inositol, choline, and other compounds to support fat metabolism. View Details: https://peptrackerpro.com/peptides/lipo-c \+ Compare: https://peptrackerpro.com/compare?select=lipo-c Track in App: https://app.peptrackerpro.com/?add=lipo-c ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. View Details: https://peptrackerpro.com/peptides/maritide \+ Compare: https://peptrackerpro.com/compare?select=maritide Track in App: https://app.peptrackerpro.com/?add=maritide ### MBX 4291 Low Evidence A GLP-1/GIP co-agonist prodrug engineered for once-monthly dosing using MBX Biosciences' PEP platform. Phase 1 blinded data showed 7% mean weight loss at 8 weeks with minimal GI side effects. View Details: https://peptrackerpro.com/peptides/mbx-4291 \+ Compare: https://peptrackerpro.com/compare?select=mbx-4291 Track in App: https://app.peptrackerpro.com/?add=mbx-4291 ### MBX 5765 Low Evidence A novel quadruple agonist prodrug combining GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single molecule, designed for once-monthly dosing and superior efficacy. View Details: https://peptrackerpro.com/peptides/mbx-5765 \+ Compare: https://peptrackerpro.com/compare?select=mbx-5765 Track in App: https://app.peptrackerpro.com/?add=mbx-5765 ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. View Details: https://peptrackerpro.com/peptides/met-097i \+ Compare: https://peptrackerpro.com/compare?select=met-097i Track in App: https://app.peptrackerpro.com/?add=met-097i ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### MOTS-c Low Evidence A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Longevity (https://peptrackerpro.com/benefits/longevity)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+2 more View Details: https://peptrackerpro.com/peptides/mots-c \+ Compare: https://peptrackerpro.com/compare?select=mots-c Track in App: https://app.peptrackerpro.com/?add=mots-c ### MT-2 (Melanotan II) Medium Evidence A melanocortin receptor agonist studied for tanning, sexual function, and appetite suppression. Pigmentation: https://peptrackerpro.com/benefits/pigmentation Sexual Health: https://peptrackerpro.com/benefits/sexual-health Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/mt-2 \+ Compare: https://peptrackerpro.com/compare?select=mt-2 Track in App: https://app.peptrackerpro.com/?add=mt-2 ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/na-931 \+ Compare: https://peptrackerpro.com/compare?select=na-931 Track in App: https://app.peptrackerpro.com/?add=na-931 ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. View Details: https://peptrackerpro.com/peptides/orforglipron \+ Compare: https://peptrackerpro.com/compare?select=orforglipron Track in App: https://app.peptrackerpro.com/?add=orforglipron ### Pemvidutide Medium Evidence A GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Liver Health: https://peptrackerpro.com/benefits/liver-health Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/pemvidutide \+ Compare: https://peptrackerpro.com/compare?select=pemvidutide Track in App: https://app.peptrackerpro.com/?add=pemvidutide ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Sleep: https://peptrackerpro.com/benefits/sleep View Details: https://peptrackerpro.com/peptides/pep19 \+ Compare: https://peptrackerpro.com/compare?select=pep19 Track in App: https://app.peptrackerpro.com/?add=pep19 ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. View Details: https://peptrackerpro.com/peptides/petrelintide \+ Compare: https://peptrackerpro.com/compare?select=petrelintide Track in App: https://app.peptrackerpro.com/?add=petrelintide ### PF-08653944 Medium Evidence An ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned. View Details: https://peptrackerpro.com/peptides/pf-08653944 \+ Compare: https://peptrackerpro.com/compare?select=pf-08653944 Track in App: https://app.peptrackerpro.com/?add=pf-08653944 ### PTP-r Low Evidence A next-generation mitochondria-targeting peptide that induces selective adipocyte apoptosis and mitochondrial uncoupling for weight loss without systemic toxicity. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ptp-r \+ Compare: https://peptrackerpro.com/compare?select=ptp-r Track in App: https://app.peptrackerpro.com/?add=ptp-r ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Ribupatide Medium Evidence A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO. View Details: https://peptrackerpro.com/peptides/ribupatide \+ Compare: https://peptrackerpro.com/compare?select=ribupatide Track in App: https://app.peptrackerpro.com/?add=ribupatide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Sermorelin Medium Evidence A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Sleep (https://peptrackerpro.com/benefits/sleep)Recovery (https://peptrackerpro.com/benefits/recovery)+1 more View Details: https://peptrackerpro.com/peptides/sermorelin \+ Compare: https://peptrackerpro.com/compare?select=sermorelin Track in App: https://app.peptrackerpro.com/?add=sermorelin ### SLU-PP-332 Low Evidence A synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health. Energy: https://peptrackerpro.com/benefits/energy Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/slu-pp-332 \+ Compare: https://peptrackerpro.com/compare?select=slu-pp-332 Track in App: https://app.peptrackerpro.com/?add=slu-pp-332 ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Taldefgrobep Alfa Low Evidence A novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/taldefgrobep \+ Compare: https://peptrackerpro.com/compare?select=taldefgrobep Track in App: https://app.peptrackerpro.com/?add=taldefgrobep ### Tesamorelin High Evidence A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Metabolism: https://peptrackerpro.com/benefits/metabolism Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/tesamorelin \+ Compare: https://peptrackerpro.com/compare?select=tesamorelin Track in App: https://app.peptrackerpro.com/?add=tesamorelin ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### Trevogrumab Medium Evidence Trevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass. Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation Body Composition: https://peptrackerpro.com/benefits/body-composition Fat Loss: https://peptrackerpro.com/benefits/fat-loss Weight Management: https://peptrackerpro.com/benefits/weight-management View Details: https://peptrackerpro.com/peptides/trevogrumab \+ Compare: https://peptrackerpro.com/compare?select=trevogrumab Track in App: https://app.peptrackerpro.com/?add=trevogrumab ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. View Details: https://peptrackerpro.com/peptides/ubt251 \+ Compare: https://peptrackerpro.com/compare?select=ubt251 Track in App: https://app.peptrackerpro.com/?add=ubt251 ### VK2735 Medium Evidence An investigational oral and injectable GLP-1/GIP dual agonist showing 12.2% oral weight loss at 13 weeks at ECO 2026 and 14.7% injectable weight loss, with Phase 3 VANQUISH trials fully enrolled. View Details: https://peptrackerpro.com/peptides/vk2735 \+ Compare: https://peptrackerpro.com/compare?select=vk2735 Track in App: https://app.peptrackerpro.com/?add=vk2735 ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. View Details: https://peptrackerpro.com/peptides/wve-007 \+ Compare: https://peptrackerpro.com/compare?select=wve-007 Track in App: https://app.peptrackerpro.com/?add=wve-007 ### ARO-INHBE Low Evidence An investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/aro-inhbe \+ Compare: https://peptrackerpro.com/compare?select=aro-inhbe Track in App: https://app.peptrackerpro.com/?add=aro-inhbe ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 Track Your Research with PepTracker Pro Try the Free App → (https://app.peptrackerpro.com/)